Bortezomib in relapsed or refractory Waldenström's macroglobulinemia

Christine Chen, C. Tom Kouroukis, Darrell White, Michael Voralia, Edward Stadtmauer, A. Keith Stewart, John Wright, Jean Powers, Wendy Walsh, Elizabeth Eisenhauer

Research output: Contribution to journalArticle

24 Scopus citations

Abstract

Bortezomib is a proteasome inhibitor that induces apoptosis in primary Waldenström's macroglobulinemia (WM) cells and WM cell lines. To date, 3 clinical trials of single-agent bortezomib in WM have been published. Of the 64 patients pooled from these studies (most with relapsed/refractory disease), a 25% or greater reduction of IgM was achieved in 78%-85%. Responses were rapid in onset, suggesting a role for bortezomib in the management of hyperviscosity or other settings where rapid IgM reduction is indicated. Neuropathy appears more severe and frequent in WM than in myeloma or other indolent lymphomas treated with bortezomib. Bortezomib-based combination therapies, with consideration for attenuated or intermittent dosing of bortezomib to minimize neuropathy, are under investigation.

Original languageEnglish (US)
Pages (from-to)74-76
Number of pages3
JournalClinical Lymphoma and Myeloma
Volume9
Issue number1
DOIs
StatePublished - Jan 1 2009

Keywords

  • Hyperviscosity
  • Neuropathy
  • Neutropenia
  • Second-line treatment
  • Thrombocytopenia
  • Waldenström

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Bortezomib in relapsed or refractory Waldenström's macroglobulinemia'. Together they form a unique fingerprint.

  • Cite this

    Chen, C., Kouroukis, C. T., White, D., Voralia, M., Stadtmauer, E., Stewart, A. K., Wright, J., Powers, J., Walsh, W., & Eisenhauer, E. (2009). Bortezomib in relapsed or refractory Waldenström's macroglobulinemia. Clinical Lymphoma and Myeloma, 9(1), 74-76. https://doi.org/10.3816/CLM.2009.n.019